Paragon Therapeutics is taking eighth spinout Mentari Therapeutics public via a reverse merger with InMed Pharmaceuticals, paired with a $290 million private p…Paragon Therapeutics is taking eighth spinout Mentari Therapeutics public via a reverse merger with InMed Pharmaceuticals, paired with a $290 million private placement to advance PACAP-targeting migraine drugs.
They say stick to what you know. And Paragon Therapeutics knows how to do reverse mergers.
The hub-and-spoke biologics company is moving its migraine drug …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat…
As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a…
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™…
Regeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on…
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its…
